ReviewGastroenterology2021
Approach to the Management of Recently Diagnosed Inflammatory Bowel Disease Patients: A User's Guide for Adult and Pediatric Gastroenterologists.
Review in Gastroenterology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06945549 (Evaluation of Intestinal Lesions and Disease Activity in Inflammatory Bowel Disease Based on 18F-FAPI PET Imaging), which is not on this map. Cited by 151 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Evaluation of Intestinal Lesions and Disease Activity in Inflammatory Bowel Disease Based on 18F-FAPI PET Imaging
Who cites it
151 citing papers in PubMed, 5 syntheses or guidelines pooled it, 247 citations in OpenAlex.
- Histological interpretation and reporting of intestinal mucosal biopsies in suspected cases of inflammatory bowel disease: Joint IAPM-ISG-CCFI Working Group Recommendations.Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology · 2026Guideline
- Hormonal therapy for impaired growth due to pediatric-onset inflammatory bowel disease: a systematic review and meta-analysis with trial sequential analysis.Journal of pediatric endocrinology & metabolism : JPEM · 2025Pooled it
- The global academic distribution and changes in research hotspots of artificial intelligence in inflammatory bowel disease since 2000.Frontiers in medicine · 2025Pooled it
- Efficacy and safety of etrolizumab in the treatment of inflammatory bowel disease: a meta-analysis.PeerJ · 2024Pooled it
- Pooled it
- Fecal microbiota transplantation versus glucocorticoids for the induction of remission in mild to moderate ulcerative colitis.Journal of translational medicine · 2022Trial
- Spondyloarthritis Preceding and Following Inflammatory Bowel Disease Diagnosis and Risk Factors: A Temporal Trends Analysis in a Population-Based Cohort.Arthritis & rheumatology (Hoboken, N.J.) · 2026Article
- Endoscopic Bariatric Therapies in Inflammatory Bowel Disease: Patient Selection, Nutritional Risk, and Periprocedural Management.Metabolites · 2026Review
- Berberrubine, a Metabolite of Berberine, Attenuates Intestinal Barrier Dysfunction in Inflammatory Bowel Disease by Inhibiting STAT3.International journal of molecular sciences · 2026Article
- Systematic immunological evaluation in adult patients with inflammatory bowel disease.BMC gastroenterology · 2026Observational
- Bifidobacterium breve207-1 protects against later-life colitis following early-life antibiotic exposure by enhancing intestinal barrier and immune homeostasis.BMC gastroenterology · 2026Article
- Discovery of 7-azaindole-3-acrylamide inhibitors of inflammasomes/IL-1β for the treatment of inflammatory bowel disease.Molecular diversity · 2026Article
- Association between iron status and inflammation markers with GDF15 and BMP6 in inflammatory bowel disease: a single center cross-sectional study.BMC gastroenterology · 2026Article
- Positioning of advanced therapies in patients with moderate-to-severe Crohn's disease.Singapore medical journal · 2026Review
- Rethinking risk in Crohn's surgery: age at onset fails to predict surgical outcomes after ileocecal resection, insights from a tertiary referral center.Techniques in coloproctology · 2026Article
- Analgesic Use in Patients with Mild Inflammatory Bowel Disease-A Nationwide Cohort Study Based on Prescription Data.Journal of clinical medicine · 2026Article
- Multimodal deep learning for inflammatory bowel disease: a new frontier in cellular and molecular biomarker discovery to clinical translation.Journal of biological engineering · 2026Review
- Delays in Diagnosing Pediatric Inflammatory Bowel Disease in Korea: Impact on Disease Severity and the Need for Early Recognition.Journal of Korean medical science · 2026Article
- Sexuality and Intimacy in Inflammatory Bowel Disease: A Phenomenological Study.Healthcare (Basel, Switzerland) · 2026Article
- Harnessing Anthocyanins to Mitigate Inflammation, Dysbiosis, and Aging in the Gastrointestinal Tract.ACS pharmacology & translational science · 2026Review
91 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
Abstract
Inflammatory bowel diseases (IBDs), including Crohn's disease and ulcerative colitis, are chronic, progressive, immune-mediated diseases of adults and children that have no cure. IBD can cause significant morbidity and lead to complications such as strictures, fistulas, infections, and cancer. In children, IBD can also result in growth impairment and pubertal delays. IBD is highly heterogenous, with severity ranging from mild to severe and symptoms ranging from mild to debilitating. Delay in IBD diagnosis, especially in Crohn's disease, is common and associated with adverse outcomes. Early diagnosis and prompt institution of treatment are the cornerstones for improving outcomes and maximizing health. Early diagnosis requires a low threshold of suspicion and red flags to guide early specialist referral at the primary provider level. Although the armamentarium of IBD medications is growing, many patients will not respond to treatment, and the selection of first-line therapy is critical. Risk stratification of disease severity, based on clinical, demographic, and serologic markers, can help guide selection of first-line therapy. Clinical decision support tools, genomics, and other biomarkers of response to therapy and risk of adverse events are the future of personalized medicine. After starting appropriate therapy, it is important to confirm remission using objective end points (treat to target) with continued control of inflammation with adjustment of therapy using surrogate biomarkers (tight control). Lastly, IBD therapy extends far beyond medications, and other aspects of the overall health and wellbeing of the patient are critical. These include preventive health, nutrition, and psychobehavioral support addressing patients' concerns around complementary therapy and medication adherence, prevention of disability, and ensuring open communication.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.